New hope for tough-to-treat lung cancers as experimental drug enters human trials
NCT ID NCT05364073
Summary
This early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allist Investigative Site
Hefei, Anhui, 230001, China
-
Allist Investigative Site
Beijing, Beijing Municipality, 101119, China
-
Allist Investigative Site
Chaoyang, Beijing Municipality, 100021, China
-
Allist Investigative Site
Chongqing, Chongqing Municipality, 400030, China
-
Allist Investigative Site
Harbin, Heilongjiang, 150081, China
-
Allist Investigative Site
Zhengzhou, Henan, 450003, China
-
Allist Investigative Site
Zhengzhou, Henan, 450052, China
-
Allist Investigative Site
Wuhan, Hubei, 430022, China
-
Allist Investigative Site
Xuzhou, Jiangsu, 221000, China
-
Allist Investigative Site
Nanchang, Jianxi, 330008, China
-
Allist Investigative Site
Changchun, Jilin, 130012, China
-
Allist Investigative Site
Jinan, Shandong, 250021, China
-
Allist Investigative Site
Jinan, Shandong, 250117, China
-
Allist Investigative Site
Taiyuan, Shanxi, 030013, China
-
ArriVent Investigative Site
Prescott, Arizona, 86301, United States
-
ArriVent Investigative Site
Sacramento, California, 95817, United States
-
ArriVent Investigative Site
Whittier, California, 90603, United States
-
ArriVent Investigative Site
Celebration, Florida, 34747, United States
-
ArriVent Investigative Site
Detroit, Michigan, 48202, United States
-
ArriVent Investigative Site
Houston, Texas, 77030, United States
-
ArriVent Investigative Site
Fairfax, Virginia, 22031, United States
-
ArriVent Investigative Site
Blacktown, New South Wales, 2148, Australia
-
ArriVent Investigative Site
St Leonards, New South Wales, 2065, Australia
-
ArriVent Investigative Site
Heidelberg, Victoria, 3084, Australia
-
ArriVent Investigative Site
Lyon, 69373, France
-
ArriVent Investigative Site
Medolla, 47014, Italy
-
ArriVent Investigative Site
Chiba, Chiba, 260-0013, Japan
-
ArriVent Investigative Site
Barcelona, 08035, Spain
-
ArriVent Investigative Site
Madrid, 28033, Spain
-
ArriVent Investigative Site
Madrid, 28050, Spain
-
ArriVent Investigative Site
Valencia, 46026, Spain
-
ArriVent Investigative Site
London, NW12PG, United Kingdom
-
Arrivent Investigative Site
Edmonton, T6G 1Z2, Canada
-
Arrivent Investigative Site
Toronto, M5G 2M9, Canada
-
Arrivent Investigative Site
Toulouse, 31059, France
-
Arrivent Investigative Site
Villejuif, 94800, France
-
Arrivent Investigative Site
Ōsaka-sayama, Osaka, 589-8511, Japan
-
Arrivent Investigative Site
Chūō, Tokyo, 104-0045, Japan
-
Arrivent Investigative Site
Koto-Ku, Tokyo, 135-8550, Japan
-
Arrivent Investigative Site
Amsterdam, North Holland, 1066 CX, Netherlands
-
Arrivent Investigative Site
Gwangju, 61469, South Korea
-
Arrivent Investigative Site
Seoul, 2447, South Korea
Conditions
Explore the condition pages connected to this study.